Disc Medicine, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Disc Medicine, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($212.18M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($109.36M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($76.43M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($46.83M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($35.97M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($812.5K) | Mar 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($236.02M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($129.72M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($91.13M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($47.48M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($30.93M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($817.0K) | Mar 29, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.64M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $96.67M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $69.26M | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $33.44M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $25.17M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $28.17M | Mar 10, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.38M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $33.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $21.86M | Feb 26, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($180.39M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($93.93M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($73.46M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($42.25M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($27.53M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($416.4K) | Mar 29, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $933.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $505.0K | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $89.0K | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | $151.0K | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $68.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $22.0K | Mar 10, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $806.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $496.77M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $368.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $200.21M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $92.41M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.32M | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $53.19M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $23.61M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $14.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $30.18M | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $739.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $443.59M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $345.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $176.60M | Feb 26, 2026 |
| FY2023 | Dec 31, 2021 | ($64.20M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($28.81M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($10.43M) | Mar 10, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($510.19M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($298.00M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($188.65M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($112.22M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($65.39M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($112.82M) | Mar 10, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.15M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $192.43M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $360.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $194.61M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $88.04M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.50M | Mar 10, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $28.32M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Feb 27, 2025 |
| FY2021 | Dec 31, 2020 | $14.00M | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (45) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (40) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (45) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (40) | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 37.89M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 29.87M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 24.36M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 17.40M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 909,418 | Mar 31, 2023 |
| FY2021 | Feb 5, 2021 | 43.00M | Mar 10, 2022 |
| FY2021 | Dec 31, 2020 | 15.57M | Mar 10, 2022 |